)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Avalo Therapeutics
Avalo Therapeutics (AVTX) investor relations material
Avalo Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary23 Mar, 2026
Executive summary
Focused execution on the Phase 2 LOTUS trial for abdakibart (AVTX-009) in hidradenitis suppurativa, with topline data expected in Q2 2026.
Cash position of $98.3 million as of December 31, 2025, projected to fund operations into 2028.
Net loss for 2025 was $78.3 million, up from $35.1 million in 2024, primarily due to increased R&D and changes in warrant-related expenses.
Financial highlights
Research and development expenses rose to $50.1 million in 2025, up $25.6 million year-over-year, driven by LOTUS trial costs.
General and administrative expenses increased to $22.9 million, up $5.7 million from 2024, mainly due to stock-based compensation and headcount.
Net loss per share improved to $5.84 (basic and diluted) in 2025 from $7.94 (basic) and $20.91 (diluted) in 2024, reflecting higher share count.
Total revenues remained flat at $59,000 for both 2025 and 2024.
Cash, cash equivalents, and short-term investments totaled $98.3 million at year-end 2025.
Outlook and guidance
Topline data from the Phase 2 LOTUS trial expected in Q2 2026.
Current cash resources expected to provide operational runway into 2028.
Rationale for HiSCR75 as LOTUS primary endpoint
Assumptions supporting the 2028 runway guidance
Pipeline expansion plans for AVTX-009 beyond HS
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Avalo Therapeutics
- Abdakibart targets IL-1β in HS, aiming for best-in-class efficacy with phase 2 data due Q2 2026.AVTX
Corporate presentation23 Mar 2026 - AVTX-009 targets IL-1β in HS, with phase II-B data expected Q2 2025 and plans for broader use.AVTXLeerink Global Healthcare Conference 202610 Mar 2026
- AVTX-009 aims for superior efficacy in HS with high affinity, robust trial design, and broad potential.AVTXTD Cowen 46th Annual Health Care Conference3 Mar 2026
- AVTX-009 targets central HS inflammation, with pivotal phase II data expected next quarter.AVTXOppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026
- Phase IIb LOTUS trial for AVTX-009 in HS to report data Q2 2026, targeting IL-1 beta.AVTXGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- AVTX-009 targets IL-1β in HS, with phase IIb data expected mid-2025 and strong enrollment progress.AVTXStifel Virtual Immunology and Inflammation Forum3 Feb 2026
- Biotech aims to raise $750M for late-stage IL-1β antibody trials in immune diseases.AVTXRegistration Filing8 Jan 2026
- AVTX-009 targets IL-1β in HS, aiming for best-in-class efficacy with 2026 phase II data expected.AVTXTD Cowen 45th Annual Healthcare Conference26 Dec 2025
- Large share and warrant registration tied to pipeline expansion brings dilution and approval risks.AVTXRegistration Filing16 Dec 2025
Next Avalo Therapeutics earnings date
Q1 20268 May, 2026
Avalo Therapeutics
Next Avalo Therapeutics earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage